TP53-mut higher-risk MDS — dismal prognosis with HMA monotherapy (median OS ~6-10 mo). Ep...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-MUT-MDS-HR |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MDS-HR |
| Sources | SRC-CIVIC SRC-ESMO-MDS-2021 SRC-IPSS-M-BERNARD-2022 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | any pathogenic mutation OR del(17p) |
| Disease | DIS-MDS-HR |
| ESCAT tier | IIIB |
| Recommended combinations | clinical trial enrollment, alloSCT consideration (preferred curative path despite poor outcomes), azacitidine + venetoclax (palliative; modest CR but non-durable) |
| Evidence summary | TP53-mut higher-risk MDS — dismal prognosis with HMA monotherapy (median OS ~6-10 mo). Eprenetapopt (APR-246) Ph3 missed primary endpoint and was retired (2021). AlloSCT remains the only potentially curative option but outcomes inferior to TP53-WT. Magrolimab + azacitidine Ph3 (ENHANCE) negative. |
Notes
ESCAT IIIB. Gene-level cell — biallelic vs monoallelic distinction matters in MDS/AML (biallelic = TP53-multihit per IPSS-M / ICC 2022, far worse). Per-hotspot cells provided for the most common variants.
Used By
No reverse references found in the YAML corpus.